Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
anticancer drug
|
| gptkbp:activeDuring |
gptkb:trifluridine
tipiracil |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C12H14F3N3O5
|
| gptkbp:clinicalTrials |
palliative care
Phase II Phase III Phase I NCT02099970 NCT02278133 NCT02415090 |
| gptkbp:contraindication |
hypersensitivity to components
severe renal impairment severe liver impairment |
| gptkbp:date |
2015
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
available
warfarin oral bioavailability inhibits DNA synthesis other chemotherapy agents |
| gptkbp:endOfLife |
approximately 2 hours
|
| gptkbp:firstAwarded |
not recommended
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
important for efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lonsurf
|
| gptkbp:is_monitored_by |
renal function
liver function blood counts |
| gptkbp:isATypeOf |
301202-40-0
|
| gptkbp:mandates |
metastatic colorectal cancer
|
| gptkbp:manufacturer |
gptkb:Taiho_Pharmaceutical
|
| gptkbp:marketedAs |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:operates_in |
L01BC05
|
| gptkbp:packaging |
bottle
|
| gptkbp:patentStatus |
patented
|
| gptkbp:provides |
ASCO guidelines
NCCN_guidelines |
| gptkbp:researchFocus |
combination therapies
resistance mechanisms biomarker_identification |
| gptkbp:route |
oral
|
| gptkbp:servesLine |
recommended
|
| gptkbp:sideEffect |
anemia
fatigue nausea diarrhea antiemetics hydration therapy |
| gptkbp:storage |
room temperature
|
| gptkbp:usedFor |
treatment of colorectal cancer
|
| gptkbp:variant |
other cancer therapies
|
| gptkbp:waterManagement |
urine
|
| gptkbp:weight |
329.25 g/mol
|